Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 372Neoplasms 325Neoplasm Metastasis 288Leukemia, Myeloid, Acute 280Breast Neoplasms 272Colorectal Neoplasms 239Melanoma 193Ovarian Neoplasms 190Recurrence 184Multiple Myeloma 178Prostatic Neoplasms 158Lung Neoplasms 158Pancreatic Neoplasms 151Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 147Glioblastoma 146Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 115Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 109Brain Neoplasms 105Advanced Solid Tumors 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 102Lymphoma 102Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Lymphoma, Follicular 92Endometrial Neoplasms 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Musculoskeletal Diseases × 1 year × Clear all
NCT05451212 2025-11-10

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Cabaletta Bio

Phase 1 Completed
7 enrolled

Autoimmune Diseases, Immune System Diseases, Musculoskeletal Diseases, Myasthenia Gravis, Neuromuscular Diseases, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡